AGM / EGM Statements
July 20 2008 - 10:27AM
PR Newswire (US)
VALLEY COTTAGE, N.Y., July 20 /PRNewswire-FirstCall/ -- XTL
Biopharmaceuticals Ltd. (NASDAQ:XTLB)(TASE:XTL) announces the
results of its Annual General Meeting ("AGM") and Extraordinary
General Meeting ("EGM") held earlier today. The outcome of the AGM
was as follows: all of the resolutions passed and the existing
Directors were reappointed. The outcome of the EGM was as follows:
resolution 4 was passed; resolutions 1, 2, 3 and 5 did not pass.
ABOUT XTL BIOPHARMACEUTICALS LTD. XTL Biopharmaceuticals Ltd.
("XTL") is engaged in the development of therapeutics for the
treatment of diabetic neuropathic pain and HCV. XTL is developing
Bicifadine, a serotonin and norepinephrine reuptake inhibitor, for
the treatment of diabetic neuropathic pain, which is currently in a
Phase 2b study. XTL has out-licensed its novel pre-clinical HCV
small molecule inhibitor program. XTL also has an active
in-licensing and acquisition program designed to identify and
acquire additional drug candidates. XTL is publicly traded on the
NASDAQ and Tel-Aviv Stock Exchanges (NASDAQ:XTLB)(TASE:XTL).
DATASOURCE: XTL Biopharmaceuticals Ltd. CONTACT: Ron Bentsur of XTL
Biopharmaceuticals Ltd., Chief Executive Officer, +1-(845)-267-0707
ext. 225
Copyright
XTL Biopharmaceuticals (NASDAQ:XTLB)
Historical Stock Chart
From Jun 2024 to Jul 2024
XTL Biopharmaceuticals (NASDAQ:XTLB)
Historical Stock Chart
From Jul 2023 to Jul 2024